Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial
Novartis Pharmaceuticals
Mohamad Mohty; Gerard Socié; Jeff Szer; Dietger Niederwieser; Jason Butler; Eva Wagner-Drouet; Reuven Or; Tsila Rovenvald-Zuckerman; Sinem Civriz Bozdag; Edouard Forcade; Giovanni Grillo; Nicolaus Kröger; Friedrich Stölzel; Domenico Russo; Jaime Sanz; Rajendra Sarkar; Tommaso Stefanelli; Celine Wilke; Robert Zeiser; Nikolas von Bubnoff